Ravuconazole Eisai/Bristol-Myers Squibb.

Abstract

Eisai and Bristol-Myers Squibb (BMS) are developing the triazole, ravuconazole, as a potential treatment for fungal infection [187888]. Eisai selected the compound for further development on the basis of its good safety profile and well-balanced antifungal activity [187888]. Ravuconazole has a broader antifungal spectrum than fluconazole and itraconazole, particularly against strains of Candida krusei and Cryptococcus neoformans [271854], [342757], [370312]. By June 1999, the compound was undergoing phase II trials [327113]. In November 2001, it was reported that BMS was seeking a co-development partner for the compound [430011]. In October 2001, analysts at ABN Amro predicted sales of US $50 million in 2003 [444020].

• Authors: Sevtap Arikan, John H Rex
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 4 Pg. 555-61 (Apr 2002) ISSN: 1472-4472 [Print] England
• PMID: 12090723 (Publication Type: Journal Article, Review)

Chemical References

• Antifungal Agents
• Thiazoles
• Triazoles
• ER 30346

Topics

• Administration, Oral
• Animals
• Antifungal Agents (adverse effects, metabolism, pharmacology)
• Clinical Trials as Topic
• Humans
• Mycoses (drug therapy)
• Structure-Activity Relationship
• Thiazoles (adverse effects, metabolism, pharmacology)
• Triazoles (adverse effects, metabolism, pharmacology)